A novel factor V compound heterozygous mutation associated with thrombosis (Y1961C; FV-Kanazawa, together with 1982_1983del)

IF 5.5 2区 医学 Q1 HEMATOLOGY Journal of Thrombosis and Haemostasis Pub Date : 2024-06-29 DOI:10.1016/j.jtha.2024.06.014
{"title":"A novel factor V compound heterozygous mutation associated with thrombosis (Y1961C; FV-Kanazawa, together with 1982_1983del)","authors":"","doi":"10.1016/j.jtha.2024.06.014","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Factor (F)V is pivotal in both procoagulant and anticoagulant mechanisms. The present report describes a novel <em>F5</em> mutation in a FV-deficient patient (FV activity, 6 IU/dL; FV antigen, 32 IU/dL) complicated by recurrent deep vein thrombosis. The patient demonstrated activated protein C resistance (APCR) with compound heterozygous mutations consisting of FV-Y1961C (FV<sub>Kanazawa</sub>) and FV-1982_1983del.</p></div><div><h3>Objectives</h3><p>To clarify thrombotic mechanisms associated with this FV abnormality.</p></div><div><h3>Methods and Results</h3><p>Levels of FV-1982_1983del were below the detection sensitivity in our expression experiments using human embryonic kidney 293T cells, and analyses were targeted, therefore, on the FV-Y1961C mutation. Activated partial thromboplastin time–based clotting assays demonstrated that FV-Y1961C exhibited APCR and that the reduced activated protein C (APC) susceptibility in FVa-Y1961C resulted in a marked depression of APC-catalyzed inactivation with delayed cleavage at Arg506 and little cleavage at Arg306 with or without protein S. The APC cofactor activity of FV-Y1961C in APC-catalyzed FVIIIa inactivation promoted by Arg336 cleavage in FVIII was impaired. The binding affinity of FVa-Y1961C to phospholipid membranes was reduced in reactions involving APC/protein S–catalyzed inactivation and in prothrombinase activity. Furthermore, the addition of FVa-Y1961C to plasma failed to inhibit tissue factor–induced procoagulant function. These characteristics were similar to those of FV-W1920R (FV<sub>Nara</sub>) and FV-A2086D (FV<sub>Besançon</sub>).</p></div><div><h3>Conclusion</h3><p>We identified a compound heterozygous FV-Y1961C mutation in the C1 domain representing a novel FV mutation (FV<sub>Kanazawa</sub>) resulting in not only APCR due to impaired FVa susceptibility and FV cofactor activity for APC function but also impaired inhibition of tissue factor–induced procoagulant function. These defects in anticoagulant function associated with FV in FV-Y1961C contributed to a prothrombotic state.</p></div>","PeriodicalId":17326,"journal":{"name":"Journal of Thrombosis and Haemostasis","volume":"22 10","pages":"Pages 2810-2822"},"PeriodicalIF":5.5000,"publicationDate":"2024-06-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Thrombosis and Haemostasis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1538783624003738","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background

Factor (F)V is pivotal in both procoagulant and anticoagulant mechanisms. The present report describes a novel F5 mutation in a FV-deficient patient (FV activity, 6 IU/dL; FV antigen, 32 IU/dL) complicated by recurrent deep vein thrombosis. The patient demonstrated activated protein C resistance (APCR) with compound heterozygous mutations consisting of FV-Y1961C (FVKanazawa) and FV-1982_1983del.

Objectives

To clarify thrombotic mechanisms associated with this FV abnormality.

Methods and Results

Levels of FV-1982_1983del were below the detection sensitivity in our expression experiments using human embryonic kidney 293T cells, and analyses were targeted, therefore, on the FV-Y1961C mutation. Activated partial thromboplastin time–based clotting assays demonstrated that FV-Y1961C exhibited APCR and that the reduced activated protein C (APC) susceptibility in FVa-Y1961C resulted in a marked depression of APC-catalyzed inactivation with delayed cleavage at Arg506 and little cleavage at Arg306 with or without protein S. The APC cofactor activity of FV-Y1961C in APC-catalyzed FVIIIa inactivation promoted by Arg336 cleavage in FVIII was impaired. The binding affinity of FVa-Y1961C to phospholipid membranes was reduced in reactions involving APC/protein S–catalyzed inactivation and in prothrombinase activity. Furthermore, the addition of FVa-Y1961C to plasma failed to inhibit tissue factor–induced procoagulant function. These characteristics were similar to those of FV-W1920R (FVNara) and FV-A2086D (FVBesançon).

Conclusion

We identified a compound heterozygous FV-Y1961C mutation in the C1 domain representing a novel FV mutation (FVKanazawa) resulting in not only APCR due to impaired FVa susceptibility and FV cofactor activity for APC function but also impaired inhibition of tissue factor–induced procoagulant function. These defects in anticoagulant function associated with FV in FV-Y1961C contributed to a prothrombotic state.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
一种与血栓形成有关的新型因子 V 复合杂合突变(Y1961C;FV-Kanazawa,以及 1982_1983del)。
背景:因子 (F)V 在促凝和抗凝机制中都起着关键作用。本报告描述了一名 FV 缺乏患者(FV:C 6 IU/dL,FV:Ag 32 IU/dL)的新型 F5 基因突变,该患者患有复发性深静脉血栓。该患者表现出活化蛋白 C 抗性(APCR),存在由 FV-Y1961C (FVKanazawa) 和 FV-1982_1983del 组成的复合杂合突变。目的方法与结果:在使用 HEK293T 细胞进行的表达实验中,FV-1982_1983del 的水平低于检测灵敏度,因此分析的目标是 FV-Y1961C 突变。基于 APTT 的凝血试验表明,FV-Y1961C 表现出 APCR,FVa-Y1961C 对 APC 的敏感性降低导致 APC 催化的失活作用明显减弱,Arg506 处的裂解延迟,Arg306 处的裂解很少,无论是否有蛋白 (P)S。FV-Y1961C 在 APC 催化的 FVIIIa 失活过程中的 APC 辅因子活性受到了损害,而 FVIII 中 Arg336 的裂解促进了 FVIIIa 的失活。在涉及 APC/PS 催化的失活反应中,FVa-Y1961C 与磷脂膜的结合亲和力降低,凝血酶原活性也降低。此外,在血浆中加入 FVa-Y1961C 无法抑制组织因子 (TF) 诱导的促凝血功能。这些特征与 FV-W1920R (FVNara) 和 FV-A2086D (FVBesançon)相似。结论:我们发现了一个复合杂合子,即 C1 结构域中的 FV-Y1961C 突变,它代表了一种新型 FV 突变(FVKanazawa),不仅会因 FVa 敏感性和 FV 对 APC 功能的辅助因子活性受损而导致 APCR,还会导致对 TF 诱导的促凝血功能的抑制受损。FV-Y1961C 中与 FV 相关的这些抗凝功能缺陷导致了一种促血栓形成状态。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Journal of Thrombosis and Haemostasis
Journal of Thrombosis and Haemostasis 医学-外周血管病
CiteScore
24.30
自引率
3.80%
发文量
321
审稿时长
1 months
期刊介绍: The Journal of Thrombosis and Haemostasis (JTH) serves as the official journal of the International Society on Thrombosis and Haemostasis. It is dedicated to advancing science related to thrombosis, bleeding disorders, and vascular biology through the dissemination and exchange of information and ideas within the global research community. Types of Publications: The journal publishes a variety of content, including: Original research reports State-of-the-art reviews Brief reports Case reports Invited commentaries on publications in the Journal Forum articles Correspondence Announcements Scope of Contributions: Editors invite contributions from both fundamental and clinical domains. These include: Basic manuscripts on blood coagulation and fibrinolysis Studies on proteins and reactions related to thrombosis and haemostasis Research on blood platelets and their interactions with other biological systems, such as the vessel wall, blood cells, and invading organisms Clinical manuscripts covering various topics including venous thrombosis, arterial disease, hemophilia, bleeding disorders, and platelet diseases Clinical manuscripts may encompass etiology, diagnostics, prognosis, prevention, and treatment strategies.
期刊最新文献
Rivaroxaban, in combination with low-dose aspirin, is associated with a reduction in proinflammatory and prothrombotic circulating vesicle signatures in patients with cardiovascular disease. Thrombotic complications in pregnancy: a case-based review of the evidence. Comparative effectiveness and safety of rivaroxaban with other oral anticoagulants in older adults with nonvalvular atrial fibrillation: population-based analysis in response to updated Beers Criteria. Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 years. Insoluble proteomics analysis of acute intracranial large vessel occlusive thrombus.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1